Product information and disease descriptionPlace of product in therapyDisease description
Natural history, survival, and mortality
13 evidence topics · 9 sources
Chronic course and recurrence after remission: 2026 international guideline
“Chronic urticaria (CU) is defined as the occurrence of wheals, angioedema, or both for more than 6 weeks. CU can come with daily, or almost daily, signs and symptoms, or an intermittent/recurrent course.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CSU episodes may recur after months or years of full remission” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Since the severity of urticaria may fluctuate, and spontaneous remission may occur at any time, it is also recommended to re‐evaluate the necessity for continued or alternative drug treatment every three to 6 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Predictors of prolonged disease duration: 2026 international guideline
“In CSU, disease duration, disease activity, and response to treatment are linked to clinical characteristics and laboratory markers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For example, the presence of concomitant CIndU, high disease activity, elevated CRP and/or the presence of angioedema are indicative for a prolonged duration of CSU and suboptimal response to antihistamine treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Remission rates at years 1, 5, and 20: targeted literature review
“The objectives of this targeted literature review were to identify evidence on the clinical course of CSU, including remission rates, and to estimate cumulative remission rates for different time points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ten publications were included in this review. The proportion of patients achieving remission within year 1 ranged from 21 to 47%, while reported remission rate estimates at year 5 were 34% and 45%. Based on calculated 4-weekly remission rates, cumulative remission estimates ranged from 9 to 38% at year 1, from 29 to 71% at year 5 and from 52 to 93% at year 20. Cumulative weighted average estimates for the proportion of patients remitting at years 1, 5 and 20 were 17%, 45% and 73%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, data sources differed in terms of definitions of disease severity and remission, as well as in conclusions on influencing factors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The average disease duration in CSU has been estimated to be 5 years, although it may persist longer in severe cases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Remission and relapse clusters in chronic urticaria: electronic health record cohort of 112,443 adults
“Adults with a CU diagnosis and confirmation CU diagnosis/CU-related treatment at least 6 weeks later were identified in the Optum® de-identified Electronic Health Record dataset (2007–2018). Active CU was a period during which a patient was not in clinical remission. Clinical remission was defined as at least 12 months without CU diagnosis and/or treatment. Relapse was defined as having a CU diagnosis and/or treatment following clinical remission.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 112,443 patients were grouped into four clusters. Cluster 1 ( N = 36,690 [32.6%]) had the shortest median time to clinical remission (4.1 months) and lowest relapse rate (38.0%). Cluster 2 ( N = 29,834 [26.5%]) reached clinical remission later (10.0 months), with a higher relapse rate (52.3%). Clusters 3 ( N = 24,093 [21.4%]) and 4 ( N = 21,826 [19.4%]) had the longest median times to clinical remission (33.8 and 44.6 months) and highest relapse rates (75%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Remission of chronic urticaria: national sample cohort with 10-year follow-up
“Patients with new-onset urticaria were identified from the National Health Insurance Service-National Sample Cohort data.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 10-year cumulative incidence rate of urticaria for the general population was 4.9% and that of chronic urticaria among patients with new-onset urticaria was 7.8%. Remission rates of chronic urticaria were 52.6% at 1 year and 88.9% at 5 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Remission was achieved in the majority of patients with chronic urticaria regardless of demographic characteristics or accompanying thyroid disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Remission of chronic urticaria: 329 Korean participants in three university hospitals
“Total 329 Korean patients with CU, who had follow-ups more than 6 months after diagnosis during a 7-year period in the department of dermatology in three university hospitals were enrolled.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion recovered in 1, 3, and 5 years after the onset of CU was 10.8%, 18.8%, and 32.9%, respectively. The mean duration of CU was 6.3 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Remission in children with chronic urticaria: 77 children followed for at least 48 months
“We evaluated 77 children diagnosed with CU, who were monitored for at least 48 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Remission was defined as having no symptoms without treatment for more than 1 year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The remission rates at 6 months, 1 year, 2 years, 3 years, and 4 years after symptom onset were 22.1%, 40.3%, 52.0%, 63.7%, and 70.2%, respectively, for children with CU. For children with CSU, these values were 23.4%, 43.7%, 56.2%, 68.7%, and 75.0%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Remission in children with chronic urticaria: 92 children aged 4 to 15 years
“Children 4 to 15 years of age with CU were investigated with a complete blood cell count, erythrocyte sedimentation rate, antinuclear antibody titer, complement CH50 level, thyroid studies, autologous serum skin test, skin-prick tests, food challenges, and stool examination for parasites.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In all, 92 children (53.3% female) with CU were recruited and followed up for a median duration of 4.3 years (range 2.5-5.8 years).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Remission rates at 1, 3, and 5 years after the onset of CU symptoms were 18.5%, 54%, and 67.7%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Disease duration: physician-diagnosed CSU in a 2019 United States survey
“To estimate the burden, clinical profile, and prevalence of diagnosed CSU in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Data from respondents with physician-diagnosed CSU were collected from the 2019 National Health and Wellness Survey (NHWS).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (SD) disease duration was 11.0 (12.6) years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote